Artiva Biotherapeutics

Artiva Biotherapeutics

Artiva Biotherapeutics launched in 2019 in San Diego, founded by CEO Fred Aslan with scientific leadership from CSO Peter Flynn. The company emerged alongside the cell therapy boom but took a divergent path from the field's early leaders. While Gilead and Novartis were commercializing autologous CAR-T therapies — each dose manufactured from a patient's own cells — Artiva bet on donor-derived natural killer cells that could be manufactured in bulk, frozen, and shipped as an off-the-shelf treatment. The firm's strategy centers on its allogeneic NK cell platform, which targets hematologic malignancies and select solid tumors through ADCC-enhanced antibody combinations. Artiva's lead asset, AlloNK, has entered clinical trials in combination with rituximab for non-Hodgkin lymphoma, while a partnership with Merck pairs its cells with an anti-tumor antibody in advanced solid tumors. The company also advances AB-101, an umbilical cord blood-derived NK cell, alongside a pipeline of CAR-NK candidates engineered for persistence and tumor infiltration. Its manufacturing facility in San Diego supplies clinical and eventual commercial demand, aiming to produce thousands of doses from a single donor apheresis run — a scale advantage autologous therapies cannot match. Artiva went public on Nasdaq in July 2024, raising $167 million in an upsized IPO priced at $12 per share (per Renaissance Capital, July 2024). Prior venture backers included 5AM Ventures, venBio Partners, and RA Capital Management, with a $120 million Series B in 2021. The company reported 122 full-time employees in its S-1 filing as of early 2024. Select adjacent academic and industry collaborations with The University of Texas MD Anderson Cancer Center and its commercial supply agreement with Merck position the firm within the broader immuno-oncology ecosystem. What structurally differentiates Artiva is its hybrid operating-company and therapeutic-platform model — it is not a pure biotech asset play nor a CRO, but a manufacturer of living drugs that it both develops internally and supplies to partners. Its donor-derived NK cell approach creates a semi-commoditized cellular product that could, if the clinical data matures, turn cell therapy into a formulary item rather than an inpatient procedure. The governance rests with a board that includes venture veterans from RA Capital and venBio, with Aslan holding the operational mandate.